elan6k_103008.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For the
month of October, 2008.
Commission
File Number 001-13896
(Translation
of registrant's name into English)
Treasury
Building, Lower Grand Canal Street, Dublin 2, Ireland
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F:
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
Note:
Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K
if submitted solely to provide an attached annual report to security
holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
Note:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant's "home country"), or under the rules of the home country exchange on
which the registrant's securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant's security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether by furnishing the information contained in this Form, the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If "Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
This
Report of Foreign Issuer on Form 6-K is incorporated by reference into the
Post-Effective Amendments on Forms F-3 and S-8 to Form F-4 Registration
Statement of Elan Corporation, plc (Registration No. 333-12756), the
Registration Statement on Form F-3 of Elan Corporation, plc and Athena
Neuroscience Finance, LLC (Registration 333-13130), and the Registration
Statements on Form S-8 of Elan Corporation, plc (Registration Nos. 333-13996,
333-12344, 333-11940, 333-100556, 333-09644, 333-09284, 333-09048, 333-08384,
333-07361, 333-07136, 333-14240, 333-121021, 333-135184 and
333-135185.
30
October 2008
Elan
Corporation PLC (“Elan or the “Company”)
Tysabri
Update
On 29
October 2008 relevant regulatory agencies were notified of a confirmed case of
progressive multifocal leukoencephalopathy (PML) in a multiple sclerosis (MS)
patient treated with TYSABRI
®
in
the commercial setting in the United States. Additional information about this
case is set forth
The
diagnosis was made based upon the detection of JC Virus (JCV) DNA in the
cerebrospinal fluid (CSF) in the setting of clinical signs, symptoms and
magnetic resonance imaging (MRI) findings consistent with the diagnosis of
PML.
Background:
|
·
|
Patient
has a history of MS and prior disease modifying therapies, including
beta-interferons and glatiramer
acetate.
|
|
·
|
Patient
had also received prior therapy with methotrexate for a rheumatological
condition.
|
|
·
|
Patient
received 14 infusions of TYSABRI
monotherapy.
|
|
·
|
Clinical
vigilance led to early identification of signs and symptoms of possible
PML and to clinical evaluation which included MRI scanning and CSF
testing.
|
|
·
|
Patient
is under the care of patient’s treating
physician.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
ELAN
CORPORATION, plc
By: /s/ William F.
Daniel
William
F. Daniel
EVP,
Company Secretary
|
Date:
October 30, 2008